Syntax Research’s Quest Diagnostics DGX Stock Holding History

Syntax Research’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-67	Closed	-$8.16K	–	178
2023 Q3	$8.16K	Buy	+67	New	+$8.93K	0.01%	146

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

DSA

Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Syntax Research's DGX Position: Q4 2023 in Review

Syntax Research sold out of Quest Diagnostics (DGX) in Q4 2023, closing a stake of 67 shares — an estimated $8.16K sold.

Syntax Research first reported a position in DGX in Q3 2023 and held it in 1 quarter. The position peaked at $8.16K in Q3 2023. 826 funds tracked by Wall St. Rank hold DGX as of Q4 2023.

Syntax Research reported no remaining Quest Diagnostics position as of Q4 2023 after selling out during the quarter.
Syntax Research sold 67 Quest Diagnostics shares in Q4 2023, an estimated $8.16K.
Syntax Research first reported a position in Quest Diagnostics in Q3 2023 and held it in 1 quarter.
Syntax Research's Quest Diagnostics position peaked at $8.16K in Q3 2023.
826 funds tracked by Wall St. Rank held Quest Diagnostics as of Q4 2023.

Based on Syntax Research's 13F filing for Q4 2023, filed 30 Jan 2024.